Last Updated March 31, 2026

VETMEDIN®(pimobendan) Chewable Tablets and VETMEDIN Solution (pimobendan oral solution) have been approved by the FDA for the delay of onset of congestive heart failure (CHF) in dogs with Stage B2 preclinical myxomatous mitral valve disease (MMVD). VETMEDIN is the only medication approved to treat preclinical heart disease in dogs and prolong their symptom-free life.

This approval is the first time the FDA has granted a full approval of an animal drug indication that was initially conditionally approved under the agency's expanded conditional approval authority. The full approval was based on two multi-site studies. In the EPIC study, VETMEDIN delayed the onset of CHF or cardiac-related death by up to an average of 15.6 months in dogs with Stage B2 preclinical MMVD, compared to the control arm.¹ In a second study, 79% of dogs with Stage B2 preclinical MMVD were successfully treated with VETMEDIN for one year without developing CHF.²

The approval adds an additional indication to those already included in the VETMEDIN label - the management of the signs of mild, moderate, or severe congestive heart failure in dogs due to clinical MMVD or dilated cardiomyopathy(DCM), for use with concurrent therapy for congestive heart failure(e.g., furosemide, etc.) as appropriate on a case-by-case basis. Studies have shown that VETMEDIN can help improve the survival time and quality of life for dogs with CHF due to MMVD or DCM. ^3-5

With the recently approved B2 indication, the VETMEDIN portfolio is the only one with both chewable tablets 
and an oral solution that is approved by the FDA to treat canine patients starting at the Stage B2 preclinical phase of MMVD, as well as Stages C and D of CHF due to MMVD or DCM.

See below for updated documentation related to safety and prescribing information and packaging and shipping updates